Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model.
Animals
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Cell Line, Tumor
Cisplatin
/ administration & dosage
Disease Models, Animal
Doxorubicin
/ administration & dosage
Drug Resistance, Neoplasm
/ genetics
Humans
Mice
Neoplasm Recurrence, Local
/ drug therapy
Osteosarcoma
/ drug therapy
Piperazines
/ administration & dosage
Pyridines
/ administration & dosage
Sorafenib
/ administration & dosage
Tumor Burden
/ drug effects
Xenograft Model Antitumor Assays
Osteosarcoma
PDOX
combination therapy
palbociclib
sorafenib
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
06
06
2019
revised:
28
06
2019
accepted:
01
07
2019
entrez:
2
8
2019
pubmed:
2
8
2019
medline:
8
8
2019
Statut:
ppublish
Résumé
Recurrent osteosarcoma is a recalcitrant disease; therefore, an improved strategy is urgently needed to provide therapy. In order to develop a novel strategy for this disease, our lab has developed a patient-derived orthotopic xenograft (PDOX) mouse model for osteosarcoma. The combination of sorafenib (SFN) and palbociclib (PAL) was shown to be effective of hepatocellular carcinoma. However, whether this combination is efficacious on osteosarcoma has not been reported. The aim of this study was to determine the efficacy of the SFN and PAL combination on a cisplatinum (CDDP)-resistant osteosarcoma PDOX model. Osteosarcoma PDOX models were randomly divided into five treatment groups: untreated-control, CDDP, SFN, PAL and the combination of SFN and PAL. Of these agents, the SFN-PAL combination significantly regressed tumor growth, and enhanced tumor necrosis with degenerative changes in the osteosarcoma PDOX. The SFN-PAL combination is an effective treatment strategy for osteosarcoma and therefore holds promise for clinical efficacy.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Recurrent osteosarcoma is a recalcitrant disease; therefore, an improved strategy is urgently needed to provide therapy. In order to develop a novel strategy for this disease, our lab has developed a patient-derived orthotopic xenograft (PDOX) mouse model for osteosarcoma. The combination of sorafenib (SFN) and palbociclib (PAL) was shown to be effective of hepatocellular carcinoma. However, whether this combination is efficacious on osteosarcoma has not been reported. The aim of this study was to determine the efficacy of the SFN and PAL combination on a cisplatinum (CDDP)-resistant osteosarcoma PDOX model.
MATERIALS AND METHODS
METHODS
Osteosarcoma PDOX models were randomly divided into five treatment groups: untreated-control, CDDP, SFN, PAL and the combination of SFN and PAL.
RESULTS
RESULTS
Of these agents, the SFN-PAL combination significantly regressed tumor growth, and enhanced tumor necrosis with degenerative changes in the osteosarcoma PDOX.
CONCLUSION
CONCLUSIONS
The SFN-PAL combination is an effective treatment strategy for osteosarcoma and therefore holds promise for clinical efficacy.
Identifiants
pubmed: 31366491
pii: 39/8/4079
doi: 10.21873/anticanres.13565
doi:
Substances chimiques
Piperazines
0
Pyridines
0
Doxorubicin
80168379AG
Sorafenib
9ZOQ3TZI87
palbociclib
G9ZF61LE7G
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4079-4084Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.